Jakafi Medication Cost
The cost of Jakafi (ruxolitinib) can vary significantly. For example, a 30-day supply of 5 mg tablets has been listed at around $13,000, with the price for 10 mg tablets reaching approximately $13,600 for a similar duration [1]. Other dosages, such as 15 mg, could cost upwards of $12,000 for a month's supply [1]. These figures represent the retail price and do not include insurance or patient assistance programs.
How Can Patients Reduce Jakafi Costs?
Patients may explore several avenues to manage the cost of Jakafi. The manufacturer, Incyte, offers a program called IncyteCARES, which provides financial assistance to eligible patients who have commercial insurance [2]. This program can help with out-of-pocket expenses, such as co-pays and deductibles [2]. For patients without commercial insurance, IncyteCARES may offer support through the IncyteCARES Foundation for those who qualify based on financial need [2]. Additionally, some pharmacies may offer discount cards or savings programs that could reduce the out-of-pocket cost [1].
What is Jakafi Used For?
Jakafi is a prescription medication approved to treat several conditions. It is indicated for adults and children aged 12 years and older with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea [3]. It is also used to treat intermediate or high-risk primary or secondary myelofibrosis (MF), including myelofibrosis that follows polycythemia vera (post-PV MF) and post-essential thrombocythemia MF [3]. Furthermore, Jakafi is prescribed for steroid-refractory acute graft-versus-host disease (GVHD) in pediatric patients 12 years and older and adult patients after failure of at least two prior lines of systemic therapy [3].
When Does Jakafi's Patent Expire?
Information regarding the specific patent expiry dates for Jakafi is available through resources that track drug patents and exclusivity periods. DrugPatentWatch.com is a platform that provides such data [4]. Generally, drug patents have a limited lifespan, after which generic versions of the medication may become available, potentially lowering costs.
Can Other Medications Be Used Instead of Jakafi?
Treatment options for the conditions Jakafi addresses can include other medications and therapies, depending on the specific diagnosis and patient factors. For polycythemia vera, treatments might include phlebotomy, interferon therapy, or other JAK inhibitors [5]. In myelofibrosis, treatment approaches can involve other JAK inhibitors, chemotherapy, or stem cell transplantation [6]. For acute graft-versus-host disease, various immunosuppressive therapies are used [7]. The choice of treatment is individualized and determined by a healthcare provider.
Who Manufactures Jakafi?
Jakafi is manufactured by Incyte Corporation [8].
---
Sources:
1. GoodRx, "Jakafi Prices, Coupons & Patient Assistance Programs," https://www.goodrx.com/jakafi
2. IncyteCARES, "Get Started with IncyteCARES," https://www.incytecares.com/
3. U.S. Food & Drug Administration, "FDA Approved Drugs," https://www.fda.gov/drugs/informationondrugs/approveddrugs/ (Search for Jakafi)
4. DrugPatentWatch.com, https://www.drugpatentwatch.com/
5. National Organization for Rare Disorders (NORD), "Polycythemia Vera," https://rarediseases.org/rare-diseases/polycythemia-vera/
6. Leukemia & Lymphoma Society, "Myelofibrosis," https://www.lls.org/disease-information/myelofibrosis
7. National Institutes of Health (NIH), "Graft Versus Host Disease," https://www.cancer.gov/publications/dictionaries/cancer-terms/def/graft-versus-host-disease
8. Incyte Corporation, "Our Medicines," https://www.incyte.com/our-products/our-medicines/